Tag: KDC-MN-377

  • D-Cycloserine

    NMDA receptor glycine-site partial agonist

    An antibiotic with NMDA receptor partial agonist activity; investigated as an extinction-learning enhancer in exposure therapy for anxiety disorders.

    Abstract

    D-cycloserine ((4R)-4-amino-1,2-oxazolidin-3-one; CAS 68-41-7; molecular formula C3H6N2O2; molecular weight 102.09) is a cyclic amino acid antibiotic isolated from Streptomyces orchidaceus and approved by the FDA in 1956 for second-line tuberculosis treatment. The compound is a partial agonist at the NMDA receptor glycine site (intrinsic activity approximately 40 to 60 percent), and the partial agonism produces dose-dependent NMDA receptor modulation: at low concentrations relative to endogenous glycine/D-serine, D-cycloserine functions as a positive modulator (enhancing NMDA function); at higher concentrations it competes with the full-agonist endogenous co-agonists and behaves as a functional antagonist. The lower-dose facilitating effect underlies use as an extinction-learning enhancer in exposure therapy for phobia, PTSD, OCD, and social anxiety; clinical trials have shown modest effects with timing-dependent results (administration shortly before therapy session is critical). Plasma half-life is approximately 10 hours. Used as the canonical NMDA glycine-site partial agonist in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.